Title
Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
A Prospective, Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Phase
Phase 2Lead Sponsor
Senju PharmaceuticalsStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Allergic ConjunctivitisIntervention/Treatment
ketotifen olopatadine methylcellulose ...Study Participants
122This is a phase 2 study that will consist of 4 visits over a 5 week period. Drug will be evaluated using the conjunctival allergen challenge model of allergic conjunctivitis.
This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
The control is a placebo patch that contains only the inactive ingredients of ketotifen.
1 gtt/eye on two separate occasions
1 gtt/eye on two separate occasions
Inclusion Criteria: 18 years of age of either sex and any race positive history of ocular allergies and a positive skin test reaction to cat hair, cat dander, dog dander, grasses, ragweed, trees, dust mites, and/or cockroaches within the past 24 months able and willing to avoid all disallowed medication for the washout period and during the study Exclusion Criteria: active ocular infection or skin condition ocular surgery within the past 3 months pregnancy or nursing